This continuing feature will focus on recent advancements in the areas of pediatrics and neonatal pharmacology and on methods for reducing medication error risk in this patient population. Most pharmacological agents are designed with the adult in mind, and there is little literature-based data from which to derive dosing schedules and proper drug administration techniques for the pediatric and neonatal patient. Moreover, pharmacological response in this group is not well understood. We hope that this feature will help you provide pharmaceutical care to this high-risk population. Direct questions or comments to hospitalpharmacy@drugfacts.com.
Get full access to this article
View all access options for this article.
References
1.
WidiltzA., BarstR.J.Pulmonary arterial hypertension in children.Eur Respir J.2003; 21: 155–76.
2.
MichelakisE.D.The role of NO axis and its therapeutic implications in pulmonary arterial hypertension.Heart Fail Rev.2003; 8: 5–21.
3.
KlinsE.S., FarberH.W.Current management of primary pulmonary hypertension.Drugs.2001; 61(13): 1945–56.
4.
AdatiaI.Recent advances in pulmonary vascular disease.Curr Opin Pediatr.2002; 14: 292–297.
5.
RichS., editor. Primary pulmonary hypertension. In: Executive Summary from the World Symposium: Primary Pulmonary Hypertension.World Health Organization; 1998.
6.
GersonyW., DucG., SinclairJ.“PPC” syndrome (persistence of the fetal circulation).Circulation.1996; 40(suppl 1): 87.
7.
AikioO., SaarelaT., PokelaM.L.Nitric oxide treatment and acute pulmonary inflammatory response in very premature infants with intractable respiratory failure shortly after birth.Acta Paediatr.2003; 92: 65–9.
8.
SchreiberM.D., Gin-MestanK., MarksJ.D.Inhaled nitric oxide in premature infants with the respiratory distress syndrome.N Eng J Med.2003; 349: 2099–107.
9.
WatanabeH., OhashiK., TakeuchiK.Sildenafil for primary and secondary pulmonary hypertension.Clin Pharmacol Therapeut.2002; 71(5): 398–402.
10.
HamplV., HergetJ.Role of nitric oxide in the pathogenesis of chronic pulmonary hypertension.Physiol Rev.2000; 80(4): 1337–72.
11.
RabeK.F., TenorH., DentG.Identification of PDE isozyme in human pulmonary artery and effect of selective PDE inhibitors.Am J Physiol.1994; 266: L536–43.
12.
CarrollW.D., DhillonR.Sildenafil as a treatment for pulmonary hypertension.Arch Dis Child.2003; 88(9): 827–8.
13.
KothariS.S., DuggalB.Chronic oral sildenafil therapy in severe pulmonary artery hypertension.Indian Heart J.2002; 54(4): 404–9.
14.
AbramsD., Schulze-NeichI., MageeA.G.Sildenafil as a selective pulmonary vasodilator in childhood primary pulmonary hypertension.Heart.2000; 84(2): E4.
CorbinJ.D., FrancisS.H.Pharmacology of phospodiesterase-5 inhibitors.Int J Clin Pract.2002; 56(6): 543–9.
17.
DauganA., GrondinP., RuaultC.The discovery of tadalafil: A novel and highly selective PDE5 inhibitor. 1:5,6,11,11a-tetrahydro-1H-imidazol[1',5':1,6]pyrido[3,4-b]indole-1,3(2H)-dione analogues.J Med Chem.2003; 46: 4525–32.
18.
NicolsD., MuirheadG.J., HarnessJ.A.Pharmaocokinetics of sildenafil citrate after single oral doses in healthy male subjects: Absolute bioavailability, food effects and dose proportionality.Br J Clin Pharmacol.2002; 53: 5S–12S.
19.
MuirheadG.J., WilnerK., ColburnW.The effects of age and renal and hepatic impairment on the pharmacokinetics of sildenafil citrate.Br J Clin Pharmacol.2002; 53: 21S–30S.
20.
Data on file with Eli Lilly and Company. Indianapolis, IN; 2004
21.
Viagra [package insert].New York, NY: Pfizer; 2000.
22.
ColemanC.I., CarabinoJ.M., VergaraC.M.: Vardenafil. An oral selective phosphodiesterase 5 inhibitor for the treatment of erectile dysfunction.Formulary.2003; 38: 131–148.
23.
NahataM.C., MoroscoR.S., ZauchaJ.A.Stability of sildenafil cirtrate in two extemporaneously prepared oral dosage forms stored under refrigeration and at room temperature [abstract].New Orleans, LA: ASHP Clinical Midyear Meeting; December 2003.
